Recent News

  • Prof. Jason Benedict named a recipient of the 2024 SUNY Chancellor’s Award for Excellence.
    Prof. Jason Benedict has been named a recipient of the 2024 SUNY Chancellor’s Award for Excellence. Jason’s peers credit him with “staggering and exceptional service” to UB since joining the faculty in 2011, as well as for having made a national impact on K-12 STEM education and outreach. Read more in this UBNow article.
  • Prof. Eva Zurek named SUNY Distinguished Professor
    Professor Eva Zurek has been named SUNY Distinguished Professor, the highest faculty rank in the SUNY system. This distinction is a credit to her work at the intersection of theoretical physics, engineering, materials science, chemistry, earth and planetary sciences. Read more in this UBNow article...
  • Prof. Sherry Chemler elected as fellow of the AAAS
    Professor Sherry Chemler has been elected as a fellow of the American Association for the Advancement of Science (AAAS) for her distinguished contributions to synthetic chemistry, including developing new copper-catalyzed alkene additions that enable concise de novo synthesis of enantioenriched saturated nitrogen and oxygen heterocycles. Read more in this UBNow article...
  • Prof. Steven Ray helps distribute over 12,000 NSF eclipse glasses to local students and community centers
    Steven Ray, who is currently the principal investigator on two NSF grants related to plasma physics and mass spectrometry, applied for a small grant to distribute 12,000 eclipse glasses to local school districts and community centers. The glasses were provided by the NSF for free and come with safety instructions.
  • Heppner lab and collaborators publish study that proposes a streamlined approach to drug design
    A recent paper published in Communications Chemistry, led by research from UB Chemistry, discusses the structures and properties of EGFR bivalent inhibitors. This sheds light on ways to design new drugs more effectively. The findings are expected to influence practices across diverse small-molecule drug development programs in both academic and industrial settings, while also laying the foundation for advanced targeted cancer therapies.